title: [Ticlopidine use in Spain: a pharmacy-based drug utilization study].
abstract: BACKGROUND
  In 1997 a program was set up to improve the use of ticlopidine. In the present study we assess whether this objective was achieved.
  
  
  METHODS
  We carried out a pharmacy-based cross-sectional study.
  
  
  RESULTS
  Out of 346 patients interviewed, 56% presented an off-label indication for ticlopidine. In 23% of patients the daily dose used was lower or higher than the recommended. Only 28% patients had the fortnightly blood monitoring performed at the time of interview.
  
  
  CONCLUSIONS
  The use of ticlopidine in Spain is not consistent with the summary of product characteristics and the program set up to improve it did not achieve a satisfactory result.
authors.affiliation: División de Farmacoepidemiología y Farmacovigilancia, Agencia Española del Medicamento, Madrid.
authors.forename: A M
authors.initials: AM
authors.lastname: del Pino
authors.forename: F J
authors.initials: FJ
authors.lastname: de Abajo
authors.forename: D
authors.initials: D
authors.lastname: Montero
authors.forename: M
authors.initials: M
authors.lastname: Madurga
authors.forename: G
authors.initials: G
authors.lastname: Martín-Serrano
mesh_terms: D000368:Aged; D003430:Cross-Sectional Studies; D004363:Drug Utilization; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007407:Interviews as Topic; D008297:Male; D008875:Middle Aged; D010594:Pharmacies; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011358:Product Surveillance, Postmarketing; D013030:Spain; D013988:Ticlopidine / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine